### **Supplementary Appendix**

#### eTables and figures with legends

## eTable 1. Strengthening the reporting of observational studies in epidemiology (STROBE) Statement

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

#### eTable 2. Baseline characteristics by quartiles of RLS

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

#### eTable 3. Baseline characteristics by quartiles of EEE

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

### eTable 4. Baseline characteristics by quartiles of TEE

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

### eTable 5. Incidence rate of stroke and its subtypes among postmenopausal participants

Note: Incidence rate was expressed in 100000 person-years, RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

# eTable 6. Association between indicators of lifetime cumulative exposure due to reproductive factors and risk of incident stroke: multivariable Cox regression

Notes: \*P < 0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. Model 1 was adjusted for age at baseline. Model 2 was adjusted for age at baseline, marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension. P for trend was test based on variable containing median value for each quintile.

# eTable 7. Association between each reproductive factor and risk of incident stroke: multivariable Cox regression

Note: \*P < 0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence interval; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; OCP, oral contraceptive pill. HR was adjusted for age at baseline, marital status, residential status, education level, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension.

### eTable 8. Sensitivity analysis

Notes: \**P*<0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

#HR was adjusted for age at baseline, marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension. ##HR was adjusted for age at baseline, marital status, residential status, education level, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day.

Related drugs included angiotensin-converting enzyme inhibitors (ACEI), aspirin, beta-blocker, calcium antagonist, diuretics, statins. Related diseases included cancer, chronic heart disease, hysterectomy, psychic disorders, rheumatic heart disease, kidney disease.

# eTable 9. Association between indicators of lifetime cumulative exposure due to reproductive factors and risk of incident stroke: age-stratified multivariable Cox regression

Notes: \**P*<0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. #HR was adjusted for age at baseline, marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second-hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension.

### eFigure 1. Incidence rate of stroke and its subtypes

Notes: RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of
measurement		assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		( <u>e</u> ) Describe any sensitivity analyses

### eTable 1. Strengthening the reporting of observational studies in epidemiology (STROBE) Statement

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study-e.g., numbers potentially eligible, examined for eligibility, confirmed eligible,
		included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential
		confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (e.g., average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g.,95% confidence interval).
		Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done-e.g., analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of
		any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies,
		and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present
		article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

### eTable 2. Baseline characteristics by quartiles of RLS

Variables	Total (N=122,939)	Q1(<31.0 years) (N=28,956)	Q2(31.0-32.9 years) (N=21,375)	Q3(33.0-35.9 years) (N=38,075)	Q4(≥36.0 years) (N=34,533)	P value
Age at baseline (years)						< 0.001
M (IQR)	58.3 (54.0-65.1)	59.2 (53.6-66.3)	57.8 (53.0-64.7)	57.5 (53.5-64.4)	58.8 (55.1-64.9)	
Age of menarche (years)						< 0.001
M (IQR)	16.0 (14.0–17.0)	17.0 (15.0–18.0)	16.0 (15.0–17.0)	16.0 (15.0–17.0)	15.0 (13.0–16.0)	
Age of menopause (years)						< 0.001
M (IQR)	49.0 (47.0–51.0)	45.0 (43.0-46.0)	48.0 (47.0–49.0)	50.0 (48.0–51.0)	52.0 (51.0-54.0)	
Marital status						< 0.001
Never married or separated or widowed or divorced	21,002 (17.1)	5,543 (19.1)	3,525 (16.5)	6,058 (15.9)	5,876 (17.0)	
Married	101,937 (82.9)	23,413 (80.9)	17,850 (83.5)	32,017 (84.1)	28,657 (83.0)	
Residential area					(0000)	< 0.001
Rural	66,599 (54.2)	17,518 (60.5)	12,353 (57.8)	20,391 (53.6)	16,337 (47.3)	
Urban	56,340 (45.8)	11,438 (39.5)	9,022 (42.2)	17,684 (46.4)	18,196 (52.7)	
Education		) ( )				< 0.001
Lower than primary school	89,238 (72.6)	22,682 (78.3)	16,220 (75.9)	27,463 (72.1)	22,873 (66.2)	
Middle school	20,276 (16.5)	4,033 (13.9)	3,172 (14.8)	6,476 (17.0)	6,595 (19.1)	
High school	10,088 (8.2)	1,805 (6.3)	1,566 (7.3)	3,194 (8.4)	3,523 (10.2)	
College or higher	3,337 (2.7)	436 (1.5)	417 (2.0)	942 (2.5)	1,542 (4.5)	
Occupation						< 0.001
Agriculture or factory worker	49,487 (40.3)	13,316 (46.0)	9,430 (44.1)	15,275 (40.1)	11,466 (33.2)	
Administrator or manager or professional or technical	1,619 (1.3)	240 (0.8)	236 (1.1)	536 (1.4)	607 (1.8)	
Sales and service workers or self- employed	4,068 (3.3)	860 (3.0)	752 (3.5)	1,328 (3.5)	1,128 (3.3)	
Retired or housewife or house husband or unemployed	65,904 (53.6)	14,033 (48.5)	10,630 (49.8)	20,372 (53.5)	20,869 (60.4)	
Other or not stated	1,861 (1.5)	507 (1.7)	327 (1.5)	564 (1.5)	463 (1.3)	
Household income (¥/year)	· 、 、 /		~ /			< 0.001
<10.000	39,899 (32.5)	11,345 (39.2)	7,202 (33.7)	11,677 (30.7)	9,675 (28.0)	
10,000-19,999	35,439 (28.8)	8,441 (29.1)	6,246 (29.2)	10,988 (28.9)	9,764 (28.3)	
20,000-34,999	28,009 (22.8)	5,586 (19.3)	4,713 (22.1)	9,156 (24.0)	8,554 (24.8)	

Variables	Total (N=122,939)	Q1(<31.0 years) (N=28,956)	Q2(31.0-32.9 years) (N=21,375)	Q3(33.0-35.9 years) (N=38,075)	Q4(≥36.0 years) (N=34,533)	P value
≥35,000	19,592 (15.9)	3,584 (12.4)	3,214 (15.0)	6,254 (16.4)	6,540 (18.9)	
BMI (kg/m <sup>2</sup> )						< 0.001
<18.5	6,374 (5.2)	2,024 (7.0)	1,208 (5.7)	1,908 (5.0)	1,234 (3.6)	
18.5-23.9	56,400 (45.9)	14,315 (49.4)	10,420 (48.7)	17,384 (45.7)	14,281 (41.4)	
24.0-27.9	43,163 (35.1)	9,187 (31.7)	7,133 (33.4)	13,609 (35.7)	13,234 (38.3)	
$\geq 28$	17,002 (13.8)	3,430 (11.9)	2,614 (12.2)	5,174 (13.6)	5,784 (16.7)	
WC (cm)						< 0.001
M (IQR)	80.2 (73.5-87.1)	79.3 (72.3-86.3)	79.6 (73.0-86.5)	80.3 (73.5-87.0)	81.5 (75.0-88.1)	
Smoking status					· · · · · ·	< 0.001
Never or occasional or former	118,408 (96.3)	27,579 (95.2)	20,573 (96.2)	36,792 (96.6)	33,464 (96.9)	
Current	4,531 (3.7)	1,377 (4.8)	802 (3.8)	1,283 (3.4)	1,069 (3.1)	
Second-hand smoking						< 0.001
Occasionally	56,434 (45.9)	12,628 (43.6)	9,445 (44.2)	17,591 (46.2)	16,770 (48.6)	
Most days	66,505 (54.1)	16,328 (56.4)	11,930 (55.8)	20,484 (53.8)	17,763 (51.4)	
Drinking status						0.041
Never or occasional or former	118,083 (96.1)	27,741 (95.8)	20,511 (96.0)	36,629 (96.2)	33,202 (96.1)	
Current	4,856 (3.9)	1,215 (4.2)	864 (4.0)	1,446 (3.8)	1,331 (3.9)	
Physical activity in MET (hours/day)						< 0.001
M (IQR)	13.5 (8.9–21.8)	13.8 (8.8–22.8)	14.0 (8.9–22.9)	13.6 (8.9–22.0)	12.7 (8.6-20.0)	
History of anticoagulation therapy						0.001
No	121,338 (98.7)	28,637 (98.9)	21,097 (98.7)	37,576 (98.7)	34,028 (98.5)	
Yes	1,601 (1.3)	319 (1.1)	278 (1.3)	499 (1.3)	505 (1.5)	
History of hypolipidemic therapy						0.005
No	122,532 (99.7)	28,874 (99.7)	21,317 (99.7)	37,953 (99.7)	34,388 (99.6)	
Yes	407 (0.3)	82 (0.3)	58 (0.3)	122 (0.3)	145 (0.4)	
History of diabetes						< 0.001
No	111,607 (90.8)	26,616 (91.9)	19,676 (92.1)	34,656 (91.0)	30,659 (88.8)	
Yes	11,332 (9.2)	2,340 (8.1)	1,699 (7.9)	3,419 (9.0)	3,874 (11.2)	
History of hypertension						< 0.001
No	67,355 (54.8)	16,642 (57.5)	12,139 (56.8)	21,057 (55.3)	17,517 (50.7)	
Yes	55,584 (45.2)	12,314 (42.5)	9,236 (43.2)	17,018 (44.7)	17,016 (49.3)	
Number of pregnancies						< 0.001

Variables	Total (N=122,939)	Q1(<31.0 years) (N=28,956)	Q2(31.0-32.9 years) (N=21,375)	Q3(33.0-35.9 years) (N=38,075)	Q4(≥36.0 years) (N=34,533)	P value
M (IQR)	4.0 (3.0–5.0)	4.0 (3.0–5.0)	4.0 (3.0–5.0)	4.0 (3.0–5.0)	4.0 (3.0–5.0)	
Number of live births						< 0.001
M (IQR)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	3.0 (2.0-3.0)	3.0 (2.0-4.0)	
Number of stillbirths						< 0.001
M (IQR)	0.0(0.0-0.0)	0.0 (0.0-0.0)	0.0(0.0-0.0)	0.0 (0.0 - 0.0)	0.0 (0.0-0.0)	
Number of miscarriages or terminations						< 0.001
M (IQR)	1.0 (0.0-2.0)	1.0 (0.0–1.0)	1.0 (0.0-2.0)	1.0 (0.0-2.0)	1.0 (0.0-2.0)	
Lifetime lactation duration (years)						< 0.001
M (IQR)	3.0 (2.0-5.0)	3.4 (2.0-5.8)	3.0 (2.0-5.0)	3.0 (1.9–5.0)	3.0 (1.8-4.9)	
History of OCP use						< 0.001
No	110,364 (89.8)	26,643 (92.0)	19,284 (90.2)	33,999 (89.3)	30,438 (88.1)	
Yes	12,575 (10.2)	2,313 (8.0)	2,091 (9.8)	4,076 (10.7)	4,095 (11.9)	
OCP use duration (years)						< 0.001
M (IQR)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	
EEE (years)	· · · ·				· · · ·	< 0.001
M (IQR)	27.3 (23.5-30.7)	22.0 (18.8–24.6)	25.8 (23.1–27.8)	28.5 (25.8-30.4)	32.0 (29.3-34.2)	
TEE (years)		. ,				< 0.001
M (IQR)	32.5 (29.3-35.3)	27.3 (24.8–29.3)	30.8 (29.3–31.8)	33.3 (31.8–34.5)	36.8 (35.3-38.6)	
Total stroke		. ,				< 0.001
Non-stroke	107,800 (87.7)	25,312 (87.4)	18,880 (88.3)	33,633 (88.3)	29,975 (86.8)	
Total stroke	15,139 (12.3)	3,644 (12.6)	2,495 (11.7)	4,442 (11.7)	4,558 (13.2)	
IS						< 0.001
Non-IS	110,086 (89.5)	25,919 (89.5)	19,267 (90.1)	34,324 (90.1)	30,576 (88.5)	
IS	12,853 (10.5)	3,037 (10.5)	2,108 (9.9)	3,751 (9.9)	3,957 (11.5)	
ICH		,	/	· · · · /		< 0.001
Non-ICH	120,359 (97.9)	28,255 (97.6)	20,934 (97.9)	37,303 (98.0)	33,867 (98.1)	
ICH	2,580 (2.1)	701 (2.4)	441 (2.1)	772 (2.0)	666 (1.9)	
SAH	,		× ,	× /	× /	0.205
Non-SAH	122,670 (99.8)	28,900 (99.8)	21,336 (99.8)	37,990 (99.8)	34,444 (99.7)	
SAH	269 (0.2)	56 (0.2)	39 (0.2)	85 (0.2)	89 (0.3)	

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

### eTable 3. Baseline characteristics by quartiles of EEE

Variables	Total (N=122,939)	Q1(<23.5 years) (N=30,125)	Q2(23.5-27.2 years) (N=29,936)	Q3(27.3-30.6 years) (N=31,990)	Q4(≥30.7 years) (N=30,888)	P value
Age at baseline (years)						< 0.001
M (IQR)	58.3 (54.0-65.1)	63.3 (57.0–69.2)	58.9 (54.0-65.4)	56.8 (53.1-62.4)	56.3 (53.6–61.0)	
Age of menarche (years)						< 0.001
M (IQR)	16.0 (14.0–17.0)	16.0 (15.0–17.0)	16.0 (15.0–17.0)	16.0 (15.0–17.0)	15.0 (13.0–16.0)	
Age of menopause (years)						< 0.001
M (IQR)	49.0 (47.0–51.0)	46.0 (43.0–48.0)	48.0 (46.0–50.0)	50.0 (48.0–51.0)	52.0 (50.0-53.0)	
Marital status						< 0.001
Never married or separated or	21,002 (17.1)	7,396 (24.6)	5,146 (17.2)	4,453 (13.9)	4,007 (13.0)	
widowed or divorced Married	101,937 (82.9)	22,729 (75.4)	24,790 (82.8)	27,537 (86.1)	26,881 (87.0)	
Residential area	101,957 (82.9)	22,729(73.4)	24,790 (82.8)	27,557 (80.1)	20,001 (07.0)	< 0.001
Rural	66,599 (54.2)	21,338 (70.8)	17,934 (59.9)	16,541 (51.7)	10,786 (34.9)	<0.001
Urban	56,340 (45.8)	8,787 (29.2)	12,002 (40.1)	15,449 (48.3)	20,102 (65.1)	
Education	50,540 (45.8)	0,707 (29.2)	12,002 (40.1)	15,449 (40.5)	20,102 (05.1)	< 0.001
Lower than primary school	89,238 (72.6)	26,701 (88.6)	23,747 (79.3)	22,583 (70.6)	16,207 (52.5)	<0.001
Middle school	20,276 (16.5)	2,492 (8.3)	4,056 (13.6)	5,753 (18.0)	7,975 (25.8)	
High school	10,088 (8.2)	791 (2.6)	1,739 (5.8)	2,844 (8.9)	4,714 (15.3)	
College or higher	3,337 (2.7)	141 (0.5)	394 (1.3)	810 (2.5)	1,992 (6.4)	
Occupation	0,007 (217)				1,22 (011)	< 0.001
Agriculture or factory worker	49,487 (40.3)	14,500 (48.1)	13,803 (46.1)	12,974 (40.5)	8,210 (26.6)	
Administrator or manager or professional or technical	1,619 (1.3)	51 (0.2)	188 (0.6)	404 (1.3)	976 (3.1)	
Sales and service workers or self- employed	4,068 (3.3)	429 (1.4)	849 (2.9)	1,280 (4.0)	1,510 (4.9)	
Retired or housewife or house husband or unemployed	65,904 (53.6)	14,755 (49.0)	14,613 (48.8)	16,797 (52.5)	19,739 (63.9)	
Other or not stated	1,861 (1.5)	390 (1.3)	483 (1.6)	535 (1.7)	453 (1.5)	
Household income (¥/year)						< 0.001
<10,000	39,899 (32.5)	15,517 (51.5)	10,396 (34.7)	8,504 (26.6)	5,482 (17.7)	
10,000-19,999	35,439 (28.8)	8,316 (27.6)	9,079 (30.3)	9,281 (29.0)	8,763 (28.4)	
20,000-34,999	28,009 (22.8)	4,030 (13.4)	6,453 (21.6)	8,271 (25.9)	9,255 (30.0)	
≥35,000	19,592 (15.9)	2,262 (7.5)	4,008 (13.4)	5,934 (18.5)	7,388 (23.9)	

Variables	Total (N=122,939)	Q1(<23.5 years) (N=30,125)	Q2(23.5-27.2 years) (N=29,936)	Q3(27.3-30.6 years) (N=31,990)	Q4(≥30.7 years) (N=30,888)	P value
BMI (kg/m <sup>2</sup> )						< 0.001
<18.5	6,374 (5.2)	2,244 (7.4)	1,727 (5.8)	1,437 (4.5)	966 (3.1)	
18.5-23.9	56,400 (45.9)	14,670 (48.7)	14,093 (47.1)	14,824 (46.3)	12,813 (41.5)	
24.0-27.9	43,163 (35.1)	9,517 (31.6)	10,178 (34.0)	11,345 (35.5)	12,123 (39.3)	
$\geq 28$	17,002 (13.8)	3,694 (12.3)	3,938 (13.1)	4,384 (13.7)	4,986 (16.1)	
WC (cm)						< 0.001
M (IQR)	80.2 (73.5-87.1)	80.0 (73.0-87.2)	80.1 (73.1-87.2)	80.0 (73.4-87.0)	81.0 (74.5-87.3)	
Smoking status					· · · · ·	< 0.001
Never or occasional or former	118,408 (96.3)	28,535 (94.7)	28,789 (96.2)	30,974 (96.8)	30,110 (97.5)	
Current	4,531 (3.7)	1,590 (5.3)	1,147 (3.8)	1,016 (3.2)	778 (2.5)	
Second-hand smoking						< 0.001
Occasionally	56,434 (45.9)	13,286 (44.1)	13,176 (44.0)	14,664 (45.8)	15,308 (49.6)	
Most days	66,505 (54.1)	16,839 (55.9)	16,760 (56.0)	17,326 (54.2)	15,580 (50.4)	
Drinking status						0.126
Never or occasional or former	118,083 (96.1)	28,890 (95.9)	28,805 (96.2)	30,754 (96.1)	29,634 (95.9)	
Current	4,856 (3.9)	1,235 (4.1)	1,131 (3.8)	1,236 (3.9)	1,254 (4.1)	
Physical activity in MET (hours/day)						< 0.001
M (IQR)	13.5 (8.9–21.8)	12.4 (8.4–21.3)	13.9 (8.9–22.5)	14.0 (9.3–22.7)	13.1 (8.9–20.2)	
History of anticoagulation therapy						< 0.001
No	121,338 (98.7)	29,674 (98.5)	29,528 (98.6)	31,638 (98.9)	30,498 (98.7)	
Yes	1,601 (1.3)	451 (1.5)	408 (1.4)	352 (1.1)	390 (1.3)	
History of hypolipidemic therapy						0.054
No	122,532 (99.7)	30,003 (99.6)	29,850 (99.7)	31,894 (99.7)	30,785 (99.7)	
Yes	407 (0.3)	122 (0.4)	86 (0.3)	96 (0.3)	103 (0.3)	
History of diabetes						< 0.001
No	111,607 (90.8)	27,440 (91.1)	27,358 (91.4)	29,103 (91.0)	27,706 (89.7)	
Yes	11,332 (9.2)	2,685 (8.9)	2,578 (8.6)	2,887 (9.0)	3,182 (10.3)	
History of hypertension						< 0.001
No	67,355 (54.8)	15,128 (50.2)	16,337 (54.6)	18,318 (57.3)	17,572 (56.9)	
Yes	55,584 (45.2)	14,997 (49.8)	13,599 (45.4)	13,672 (42.7)	13,316 (43.1)	
Number of pregnancies						< 0.001
M (IQR)	4.0 (3.0-5.0)	5.0 (4.0-6.0)	4.0 (3.0–5.0)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	
Number of live births						< 0.001

Variables	Total (N=122,939)	Q1(<23.5 years) (N=30,125)	Q2(23.5-27.2 years) (N=29,936)	Q3(27.3-30.6 years) (N=31,990)	Q4(≥30.7 years) (N=30,888)	P value
M (IQR)	3.0 (2.0-4.0)	4.0 (3.0–5.0)	3.0 (2.0-4.0)	2.0 (2.0-3.0)	2.0 (1.0-2.0)	
Number of stillbirths						< 0.001
M (IQR)	0.0(0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	
Number of miscarriages or terminations						< 0.001
M (IQR)	1.0 (0.0-2.0)	0.0 (0.0-1.0)	1.0 (0.0–2.0)	1.0 (0.0–2.0)	1.0 (0.0-2.0)	
Lifetime lactation duration(years)						< 0.001
M (IQR)	3.0 (2.0-5.0)	6.0 (4.0-8.3)	3.7 (2.3–5.0)	2.6 (1.8-4.0)	1.9 (1.0-2.7)	
History of OCP use						< 0.001
No	110,364 (89.8)	27,262 (90.5)	26,451 (88.4)	28,396 (88.8)	28,255 (91.5)	
Yes	12,575 (10.2)	2,863 (9.5)	3,485 (11.6)	3,594 (11.2)	2,633 (8.5)	
OCP use duration (years)						< 0.001
M (IQR)	0.0 (0.0 - 0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	
RLS (years)						< 0.001
M (IQR)	33.0 (31.0–36.0)	30.0 (27.0–32.0)	32.0 (30.0–34.0)	34.0 (32.0–35.0)	37.0 (35.0–39.0)	
TEE (years)						< 0.001
M (IQR)	32.5 (29.3–35.3)	26.8 (24.5–29.0)	30.8 (29.3–32.3)	33.3 (32.0–34.8)	36.8 (35.3–38.5)	
Total stroke						< 0.001
Non-stroke	107,800 (87.7)	25,500 (84.6)	26,285 (87.8)	28,587 (89.4)	27,428 (88.8)	
Total stroke	15,139 (12.3)	4,625 (15.4)	3,651 (12.2)	3,403 (10.6)	3,460 (11.2)	
IS						< 0.001
Non-IS	110,086 (89.5)	26,407 (87.7)	26,851 (89.7)	29,042 (90.8)	27,786 (90.0)	
IS	12,853 (10.5)	3,718 (12.3)	3,085 (10.3)	2,948 (9.2)	3,102 (10.0)	
ICH						< 0.001
Non-ICH	120,359 (97.9)	29,079 (96.5)	29,282 (97.8)	31,475 (98.4)	30,523 (98.8)	
ICH	2,580 (2.1)	1,046 (3.5)	654 (2.2)	515 (1.6)	365 (1.2)	
SAH						0.497
Non-SAH	122,670 (99.8)	30,057 (99.8)	29,877 (99.8)	31,925 (99.8)	30,811 (99.8)	
SAH	269 (0.2)	68 (0.2)	59 (0.2)	65 (0.2)	77 (0.2)	

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

eTable 4. Baseline characteristics by quartiles of TEE
--

Variables	Total (N=122,939)	Q1(<29.3 years) (N=29,760)	Q2(29.3-32.4 years) (N=31,647)	Q3(32.5-35.2 years) (N=29,218)	Q4(≥35.3 years) (N=32,314)	P value
Age at baseline (years)					· · · · · ·	< 0.001
M (IQR)	58.3 (54.0-65.1)	60.4 (54.6-67.3)	58.1 (53.3-64.9)	57.2 (53.4-63.6)	58.1 (54.6-64.1)	
Age of menarche (years)						< 0.001
M (IQR)	16.0 (14.0–17.0)	17.0 (15.0–17.0)	16.0 (15.0–17.0)	16.0 (14.0–17.0)	15.0 (13.0–16.0)	
Age of menopause (years)						< 0.001
M (IQR)	49.0 (47.0–51.0)	45.0 (43.0-47.0)	48.0 (47.0–50.0)	50.0 (48.0–51.0)	52.0 (50.0-54.0)	
Marital status						< 0.001
Never married or						
separated or widowed or divorced	21,002 (17.1)	6,201 (20.8)	5,300 (16.7)	4,436 (15.2)	5,065 (15.7)	
Married	101,937 (82.9)	23,559 (79.2)	26,347 (83.3)	24,782 (84.8)	27,249 (84.3)	
Residential area						< 0.001
Rural	66,599 (54.2)	20,961 (70.4)	18,230 (57.6)	14,661 (50.2)	12,747 (39.4)	
Urban	56,340 (45.8)	8,799 (29.6)	13,417 (42.4)	14,557 (49.8)	19,567 (60.6)	
Education						< 0.001
Lower than primary	89,238 (72.6)	25,282 (85.0)	24,381 (77.0)	20,432 (69.9)	19,143 (59.2)	
school	89,238 (72.0)	25,282 (85.0)		20,432 (09.9)		
Middle school	20,276 (16.5)	3,046 (10.2)	4,634 (14.6)	5,326 (18.2)	7,270 (22.5)	
High school	10,088 (8.2)	1,200 (4.0)	2,071 (6.6)	2,645 (9.1)	4,172 (12.9)	
College or higher	3,337 (2.7)	232 (0.8)	561 (1.8)	815 (2.8)	1,729 (5.4)	
Occupation						< 0.001
Agriculture or factory worker	49,487 (40.3)	15,584 (52.4)	14,052 (44.4)	11,078 (37.9)	8,773 (27.1)	
Administrator or manager						
or professional or	1,619 (1.3)	128 (0.4)	298 (1.0)	457 (1.6)	736 (2.3)	
technical						
Sales and service workers or self-employed	4,068 (3.3)	596 (2.0)	1,052 (3.3)	1,132 (3.9)	1,288 (4.0)	
Retired or housewife or						
house husband or unemployed	65,904 (53.6)	12,977 (43.6)	15,739 (49.7)	16,116 (55.1)	21,072 (65.2)	
Other or not stated	1,861 (1.5)	475 (1.6)	506 (1.6)	435 (1.5)	445 (1.4)	

Variables	Total (N=122,939)	Q1(<29.3 years) (N=29,760)	Q2(29.3-32.4 years) (N=31,647)	Q3(32.5-35.2 years) (N=29,218)	Q4(≥35.3 years) (N=32,314)	P value
Household income (¥/year)						< 0.001
<10,000	39,899 (32.5)	14,517 (48.8)	10,891 (34.4)	7,880 (27.0)	6,611 (20.4)	
10,000-19,999	35,439 (28.8)	8,484 (28.5)	9,358 (29.6)	8,431 (28.8)	9,166 (28.4)	
20,000-34,999	28,009 (22.8)	4,227 (14.2)	6,886 (21.8)	7,630 (26.1)	9,266 (28.7)	
≥35,000	19,592 (15.9)	2,532 (8.5)	4,512 (14.2)	5,277 (18.1)	7,271 (22.5)	
BMI (kg/m <sup>2</sup> )						< 0.001
<18.5	6,374 (5.2)	2,035 (6.8)	1,809 (5.7)	1,368 (4.7)	1,162 (3.6)	
18.5-23.9	56,400 (45.9)	14,627 (49.2)	15,036 (47.5)	13,254 (45.3)	13,483 (41.7)	
24.0-27.9	43,163 (35.1)	9,470 (31.8)	10,659 (33.7)	10,540 (36.1)	12,494 (38.7)	
$\geq 28$	17,002 (13.8)	3628 (12.2)	4,143 (13.1)	4,056 (13.9)	5,175 (16.0)	
WC (cm)						< 0.001
M (IQR)	80.2 (73.5-87.1)	79.8 (72.7-86.9)	80.0 (73.0-87.0)	80.3 (73.6-87.0)	81.0 (74.6-87.5)	
Smoking status						< 0.001
Never or occasional or	118,408 (96.3)	28,271 (95.0)	30,433 (96.2)	28,277 (96.8)	31,427 (97.3)	
former						
Current	4,531 (3.7)	1,489 (5.0)	1,214 (3.8)	941 (3.2)	887 (2.7)	
Second-hand smoking						< 0.001
Occasionally	56,434 (45.9)	12,614 (42.4)	13,880 (43.9)	13,648 (46.7)	16,292 (50.4)	
Most days	66,505 (54.1)	17,146 (57.6)	17,767 (56.1)	15,570 (53.3)	16,022 (49.6)	0.775
Drinking status						0.775
Never or occasional or former	118,083 (96.1)	28,560 (96.0)	30,388 (96.0)	28,084 (96.1)	31,051 (96.1)	
Current	4,856 (3.9)	1,200 (4.0)	1,259 (4.0)	1,134 (3.9)	1,263 (3.9)	
Physical activity in MET	4,000 (0.7)	1,200 (4.0)	1,239 (4.0)	1,154 (5.5)	1,205 (5.7)	
(hours/day)						< 0.001
M (IQR)	13.5 (8.9–21.8)	13.8 (8.7–23.2)	14.0 (8.9–22.7)	13.6 (8.9–21.7)	12.6 (8.6–19.6)	
History of anticoagulation	× /	× /	· /	× /	× /	0.004
therapy						0.094
No	121,338 (98.7)	29,351 (98.6)	31,246 (98.7)	28,873 (98.8)	31,868 (98.6)	
Yes	1,601 (1.3)	409 (1.4)	401 (1.3)	345 (1.2)	446 (1.4)	
History of hypolipidemic						0.514
therapy						0.314
No	122,532 (99.7)	29,663 (99.7)	31,553 (99.7)	29,120 (99.7)	32,196 (99.6)	

Variables	Total (N=122,939)	Q1(<29.3 years) (N=29,760)	Q2(29.3-32.4 years) (N=31,647)	Q3(32.5-35.2 years) (N=29,218)	Q4(≥35.3 years) (N=32,314)	P valu
Yes	407 (0.3)	97 (0.3)	94 (0.3)	98 (0.3)	118 (0.4)	
History of diabetes						< 0.001
No	111,607 (90.8)	27,390 (92.0)	29,017 (91.7)	26,474 (90.6)	28,726 (88.9)	
Yes	11,332 (9.2)	2,370 (8.0)	2,630 (8.3)	2,744 (9.4)	3,588 (11.1)	
History of hypertension						< 0.001
No	67,355 (54.8)	16,063 (54.0)	17,919 (56.6)	16,299 (55.8)	17,074 (52.8)	
Yes	55,584 (45.2)	13,697 (46.0)	13,728 (43.4)	12,919 (44.2)	15,240 (47.2)	
Number of pregnancies						< 0.001
M (IQR)	4.0 (3.0-5.0)	4.0 (3.0-5.0)	4.0 (3.0-5.0)	3.0 (2.0-5.0)	4.0 (3.0-5.0)	
Number of live births		· /				< 0.001
M (IQR)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	2.0 (2.0-3.0)	2.0 (2.0-3.0)	
Number of stillbirths		· · · ·		· · · · ·		< 0.001
M (IQR)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	
Number of miscarriages or				~ /		
terminations						< 0.001
M (IQR)	1.0 (0.0-2.0)	0.0 (0.0-1.0)	1.0 (0.0-1.0)	1.0 (0.0-2.0)	1.0 (0.0-2.0)	
Lifetime lactation duration				~ /		0.001
(years)						< 0.001
M (IQR)	3.0 (2.0-5.0)	5.5 (3.0-8.0)	3.1 (2.0-5.0)	2.8 (1.7-4.0)	2.0 (1.3-3.2)	
History of OCP use				~ /		< 0.001
No	110,364 (89.8)	28,821 (96.8)	29,705 (93.9)	26,316 (90.1)	25,522 (79.0)	
Yes	12,575 (10.2)	939 (3.2)	1,942 (6.1)	2,902 (9.9)	6,792 (21.0)	
OCP use duration (years)	)()		J- (- )			< 0.001
M (IQR)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	
RLS (years)						< 0.001
M (IQR)	33.0 (31.0-36.0)	29.0 (27.0-31.0)	32.0 (31.0-33.0)	34.0 (33.0-35.0)	37.0 (36.0-39.0)	
EEE (years)			× ,	,		< 0.001
M (IQR)	27.3 (23.5–30.7)	21.0 (18.0–23.2)	26.3 (24.5–27.8)	29.3 (27.5-30.7)	32.5 (30.3-34.3)	
Total stroke				- ( )	- (	< 0.001
Non-stroke	107,800 (87.7)	25,671 (86.3)	27,873 (88.1)	25,937 (88.8)	28,319 (87.6)	
Total stroke	15,139 (12.3)	4,089 (13.7)	3,774 (11.9)	3,281 (11.2)	3,995 (12.4)	
IS		.,	- , (/)	- , ()		< 0.001
Non-IS	110,086 (89.5)	26,423 (88.8)	28,458 (89.9)	26,407 (90.4)	28,798 (89.1)	0.001


Variables	Total (N=122,939)	Q1(<29.3 years) (N=29,760)	Q2(29.3-32.4 years) (N=31,647)	Q3(32.5-35.2 years) (N=29,218)	Q4(≥35.3 years) (N=32,314)	P value
IS	12,853 (10.5)	3,337 (11.2)	3,189 (10.1)	2,811 (9.6)	3,516 (10.9)	
ICH						< 0.001
Non-ICH	120,359 (97.9)	28,881 (97.0)	30,984 (97.9)	28,697 (98.2)	31,797 (98.4)	
ICH	2,580 (2.1)	879 (3.0)	663 (2.1)	521 (1.8)	517 (1.6)	
SAH						0.345
Non-SAH	122,670 (99.8)	29,698 (99.8)	31,588 (99.8)	29,151 (99.8)	32,233 (99.7)	
SAH	269 (0.2)	62 (0.2)	59 (0.2)	67 (0.2)	81 (0.3)	

Notes: Values are presented as number (N) with percent (%) or medians (M) with interquartile ranges (IQRs). *P* values represent statistical measurement of comparing different quartiles. BMI, body mass index; WC, waist circumference; MET, metabolic equivalents of task; OCP, oral contraceptive pill; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

		Total stroke				IS			ICH			SAH	
		Cases	Person- years	Incidence rate	Cases	Person- years	Incidenc e rate	Cases	Person- years	Incidence rate	Cases	Person- years	Incidence rate
	Q1 (<31.0 years)	3,644	247,834.8	1,470.3	3,037	24,8782.0	1,220.7	701	257,665.7	272.1	56	258,500.4	21.7
RLS	Q2 (31.0-32.9 years)	2,495	184,663.8	1,351.1	2,108	185,404.0	1,137.0	441	191,816.8	229.9	39	192,458.0	20.3
RL3	Q3 (33.0-35.9 years)	4,442	328,310.9	1,353.0	3,751	329,584.0	1,138.1	772	341,249.4	226.2	85	342,327.9	24.8
	Q4 (≥36.0 years)	4,558	294,247.5	1,549.0	3,957	295,531.5	1,338.9	666	308,249.9	216.1	89	309,314.6	28.8
	Q1 (<23.5 years)	4,625	253,381.2	1,825.3	3,718	254,547.9	1,460.6	1,046	265,006.2	394.7	68	266,065.0	25.6
FFF	Q2 (23.5-27.2 years)	3,651	258,034.5	1,414.9	3,085	259,193.7	1,190.2	654	268,567.3	243.5	59	269,678.1	21.9
EEE	Q3 (27.3-30.6 years)	3,403	278,165.3	1,223.4	2,948	279,202.1	1,055.9	515	288,627.6	178.4	65	289,468.7	22.5
	Q4 (≥30.7 years)	3,460	265,475.9	1,303.3	3,102	266,357.8	1,164.6	365	276,780.7	131.9	77	277,389.1	27.8
	Q1 (<29.3 years)	4,089	253,815.0	1,611.0	3,337	254,838.0	1,309.5	879	264,267.1	332.6	62	265,215.9	23.4
TEE	Q2 (29.3-32.4 years)	3,774	272,691.6	1,384.0	3,189	273,863.2	1,164.5	663	283,394.1	233.9	59	284,468.1	20.7
IEE	Q3 (32.5-35.2 years)	3,281	252,654.1	1,298.6	2,811	253,626.5	1,108.3	521	262,558.5	198.4	67	263,295.2	25.4
	Q4 (≥35.3 years)	3,995	275,896.2	1,448.0	3,516	276,973.8	1,269.4	517	288,762.2	179.0	81	289,621.7	28.0
	Total	15,139	1,055,056.9	1,434.9	12,853	1,059,301.5	1,213.3	2,580	1,098,981.9	234.8	269	1,102,600.9	24.4

eTable 5. Incidence rate of stroke and its subtypes among postmenopausal participants

Note: Incidence rate was expressed in 100,000 person-years, RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.



eFigure S1. Incidence rate of stroke and its subtypes

Notes: RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

e l'able	able 6. Association between indicators of lifetime cumulative exposure due to reproductive factors and risk of incident stroke: multivariable Cox regression										
		Total stroke	(HR 95%CI)	IS (HR	95%CI)	ICH (H	R 95%CI)	SAH (H	R 95%CI)		
		Model 1	Model 2	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2		
	Q1 (<31.0 years)	1.00 (0.97~1.03)	1.00 (0.97~1.03)	1.00 (0.96~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.93~1.08)	1.00 (0.77~1.30)	1.00 (0.77~1.31)		
	Q2 (31.0-32.9 years)	0.98 (0.94~1.01)	0.96 (0.92~1.00)*	0.99 (0.94~1.03)	0.96 (0.92~1.00)	0.91 (0.82~0.99)	0.93 (0.85~1.03)	0.94 (0.69~1.29)	0.94 (0.69~1.29)		
DIC	Q3 (33.0-35.9 years)	0.98 (0.95~1.01)	0.94 (0.91~0.96)	0.99 (0.96~1.02)	0.93 (0.90~0.96)	0.90 (0.84~0.97)	0.96 (0.89~1.03)	1.16 (0.94~1.43)	1.15 (0.93~1.42)		
RLS	Q4 (≥36.0 years)	1.06 (1.03~1.09)	0.95 (0.92~0.98)	1.10 (1.06~1.13)	0.95 (0.92~0.98)	0.81 (0.75~0.87)	0.87 (0.81~0.94)	1.30 (1.06~1.61)	1.27 (1.03~1.58)		
	10-year increase	1.00 (1.00~1.01)*	1.00 (1.00~1.00)	1.01 (1.01~1.02)*	1.00 (1.00~1.00)	0.98 (0.97~0.99)	0.99 (0.98~1.00)	1.01 (0.98~1.05)	1.01 (0.98~1.04)		
	P for trend	0.010	0.020	< 0.001	0.030	< 0.001	0.020	0.080	0.110		
	Q1 (<23.5 years)	1.00 (0.97~1.03)	1.00 (0.97~1.03)	1.00 (0.97~1.03)	1.00 (0.96~1.04)	1.00 (0.94~1.07)	1.00 (0.93~1.07)	1.00 (0.78~1.29)	1.00 (0.77~1.3)		
	Q2 (23.5-27.2 years)	0.95 (0.92~0.98)	0.91 (0.88~0.94)	1.00 (0.96~1.03)	0.92 (0.89~0.95)	0.75 (0.70~0.81)	0.90 (0.84~0.97)	0.94 (0.73~1.22)	0.97 (0.75~1.24)		
EEE	Q3 (27.3-30.6 years)	0.93 (0.90~0.96)	0.86 (0.83~0.89)	1.00 (0.96~1.03)	0.87 (0.84~0.90)	0.62 (0.57~0.67)	0.82 (0.75~0.89)	1.02 (0.80~1.30)	1.06 (0.83~1.35)		
LLL	Q4 (≥30.7 years)	1.03 (0.99~1.06)	0.85 (0.82~0.89)	1.14 (1.10~1.19)	0.86 (0.83~0.90)	0.47 (0.43~0.53)	0.73 (0.65~0.81)	1.28 (1.02~1.61)	1.34 (1.04~1.71)		
	10-year increase	1.00 (1.00~1.00)	0.99 (0.99~0.99)*	1.01 (1.01~1.01)*	0.99 (0.99~0.99)*	0.95 (0.94~0.96)	0.98 (0.97~0.99)	1.01 (0.99~1.04)	1.01 (0.99~1.04)		
	P for trend	0.840	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	0.160	0.130		
	Q1 (<29.3 years)	1.00 (0.97~1.03)	1.00 (0.97~1.03)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.07)	1.00 (0.93~1.07)	1.00 (0.78~1.29)	1.00 (0.77~1.3)		
	Q2 (29.3-32.4 years)	0.96 (0.93~0.99)	0.92 (0.89~0.95)	0.99 (0.95~1.02)	0.92 (0.89~0.95)	0.79 (0.74~0.86)	0.92 (0.86~1.00)*	0.92 (0.71~1.18)	0.93 (0.72~1.20)		
TEE	Q3 (32.5-35.2 years)	0.93 (0.90~0.97)	0.87 (0.84~0.90)	0.98 (0.94~1.01)	0.86 (0.83~0.89)	0.71 (0.65~0.77)	0.88 (0.81~0.96)	1.14 (0.90~1.45)	1.16 (0.91~1.47)		
TEE	Q4 (≥35.3 years)	1.00 (0.97~1.03)	0.87 (0.84~0.90)	1.07 (1.04~1.11)	0.86 (0.83~0.89)	0.61 (0.56~0.67)	0.83 (0.76~0.91)	1.23 (0.99~1.53)	1.25 (0.99~1.57)		
	10-year increase	1.00 (1.00~1.00)	0.99 (0.99~0.99)*	1.01 (1.00~1.01)*	0.99 (0.99~0.99)*	0.96 (0.95~0.97)	0.99 (0.98~0.99)*	1.02 (0.99~1.04)	1.02 (0.99~1.05)		
	<i>P</i> for trend	0.820	< 0.001	0.008	< 0.001	< 0.001	0.001	0.140	0.140		

eTable 6. Association between indicators of lifetime cumulative exposure due to reproductive factors and risk of incident stroke: multivariable Cox regression

Notes: \*P < 0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. Model 1 was adjusted for age at baseline. Model 2 was adjusted for age at baseline, marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension. *P* for trend was test based on variable containing median value for each quintile.

	Total stroke		al stroke		IS		ICH		SAH
		N (%)	HR (95%CI)	N (%)	HR (95%CI)	N (%)	HR (95%CI)	N (%)	HR (95%CI)
	Q1 (9.0-13.9 years)	1911 (12.6)	Reference	1669 (13.0)	Reference	283 (11.0)	Reference	39 (14.5)	Reference
A	Q2 (14-15.9 years)	5107 (33.7)	1.03 (0.98~1.09)	4340 (33.8)	1.02 (0.97~1.08)	871 (33.8)	1.05 (0.92~1.2)	73 (27.1)	0.72 (0.49~1.06)
Age of	Q3 (16-16.9 years)	3275 (21.6)	0.99 (0.94~1.05)	2757 (21.5)	0.98 (0.92~1.04)	569 (22.1)	1.00 (0.86~1.15)	57 (21.2)	0.83 (0.55~1.26)
menarche	Q4 (17-18 years)	4846 (32.0)	0.97 (0.92~1.02)	4087 (31.8)	0.96 (0.91~1.02)	857 (33.2)	0.97 (0.85~1.12)	100 (37.2)	0.95 (0.65~1.39)
	1-year increase	15139 (100)	0.99 (0.98~1.00)*	12853 (100)	0.99 (0.98~1.00)*	2580 (100)	0.99 (0.97~1.02)	269 (100)	1.02 (0.95~1.10)
	Q1 (40-46.9 years)	3584 (23.7)	Reference	2996 (23.3)	Reference	671 (26.0)	Reference	49 (18.2)	Reference
A	Q2 (47-48.9 years)	2989 (19.7)	0.97 (0.92~1.02)	2507 (19.5)	0.96 (0.91~1.01)	550 (21.3)	1.01 (0.90~1.13)	52 (19.3)	1.18 (0.80~1.74)
Age of	Q3 (49-50.9 years)	3773 (24.9)	0.93 (0.89~0.98)	3215 (25.0)	0.93 (0.89~0.98)	652 (25.3)	0.96 (0.86~1.07)	79 (29.4)	1.41 (0.98~2.02)
menopause	Q4 (>=51 years)	4793 (31.7)	0.93 (0.89~0.97)	4135 (32.2)	0.93 (0.89~0.98)	707 (27.4)	0.85 (0.76~0.95)	89 (33.1)	1.32 (0.92~1.88)
	1-year increase	15139 (100)	1.00 (0.99~1.00)*	12853 (100)	1.00 (0.99~1.00)*	2580 (100)	1.00 (0.98~1.00)*	269 (100)	1.02 (0.99~1.06)
	1	466 (3.1)	Reference	414 (3.2)	Reference	60 (2.3)	Reference	9 (3.4)	Reference
Nobanaf	2	1735 (11.5)	0.96 (0.86~1.06)	1527 (11.9)	0.97 (0.87~1.08)	216 (8.4)	0.79 (0.59~1.05)	40 (14.9)	1.12 (0.54~2.32)
Number of	3	3174 (21.0)	1.03 (0.94~1.14)	2748 (21.4)	1.04 (0.94~1.15)	469 (18.2)	0.91 (0.70~1.20)	60 (22.3)	1.05 (0.52~2.14)
pregnancie	4	3372 (22.3)	1.09 (0.98~1.20)	2901 (22.6)	1.10 (0.99~1.22)	523 (20.3)	0.95 (0.72~1.25)	52 (19.3)	0.96 (0.47~1.99)
S	5 or above	6392 (42.2)	1.17 (1.06~1.29)	5263 (41.0)	1.16 (1.04~1.29)	1312 (50.9)	1.16 (0.89~1.51)	108 (40.2)	1.27 (0.63~2.59)
	Each number	15139 (100)	1.04 (1.03~1.05)	12853 (100)	1.03 (1.02~1.04)	2580 (100)	1.08 (1.06~1.11)	269 (100)	1.05 (0.97~1.12)
	0	53 (0.4)	Reference	47 (0.4)	Reference	9 (0.4)	Reference	2 (0.7)	Reference
	1	1577 (10.4)	0.65 (0.50~0.86)	1410 (11.0)	0.61 (0.45~0.81)	169 (6.6)	0.70 (0.36~1.38)	37 (13.8)	0.42 (0.10~1.8)
Number of	2	3722 (24.6)	0.72 (0.55~0.95)	3278 (25.5)	0.68 (0.51~0.91)	460 (17.8)	0.65 (0.34~1.27)	77 (28.6)	0.41 (0.10~1.67)
live births	3	4110 (27.2)	0.80 (0.61~1.05)	3571 (27.8)	0.77 (0.58~1.03)	637 (24.7)	0.76 (0.39~1.46)	70 (26.0)	0.38 (0.09~1.54)
	4 or above	5677 (37.5)	0.85 (0.65~1.11)	4547 (35.4)	0.79 (0.59~1.05)	1305 (50.6)	0.92 (0.48~1.78)	83 (30.9)	0.36 (0.09~1.48)
	Each number	15139 (100)	1.06 (1.04~1.07)	12853 (100)	1.04 (1.02~1.05)	2580 (100)	1.12 (1.09~1.15)	269 (100)	0.97 (0.87~1.09)
Numberof	0	13578 (89.7)	Reference	11602 (90.3)	Reference	2211 (85.7)	Reference	234 (87.0)	Reference
Number of stillbirths	1 or more	1561 (10.3)	1.08 (1.02~1.14)	1251 (9.7)	1.07 (1.01~1.13)	369 (14.3)	1.17 (1.05~1.31)	35 (13.0)	1.47 (1.02~2.13)
sunonuis	Each number	15139 (100)	1.03 (1.00~1.07)*	12853 (100)	1.01 (0.98~1.05)	2580 (100)	1.11 (1.05~1.17)	269 (100)	1.11 (0.89~1.39)
Number of	0	6628 (43.8)	Reference	5417 (42.2)	Reference	1355 (52.5)	Reference	107 (39.8)	Reference
miscarriag	1	4434 (29.3)	1.01 (0.97~1.05)	3854 (30.0)	1.03 (0.98~1.07)	693 (26.9)	1.01 (0.92~1.11)	82 (30.5)	1.19 (0.89~1.59)
es or	2 or more	4077 (26.9)	1.04 (1.00~1.08)*	3582 (27.9)	1.04 (1.00~1.09)*	532 (20.6)	1.01 (0.91~1.12)	80 (29.7)	1.33 (0.98~1.80)
terminatio ns	Each number	15139 (100)	1.02 (1.00~1.03)*	12853 (100)	1.02 (1.00~1.03)*	2580 (100)	1.02 (0.98~1.05)	269 (100)	1.10 (0.99~1.21)
Lactation	No lactation	463 (3.1)	Reference	424 (3.3)	Reference	50 (1.9)	Reference	9 (3.4)	Reference
Luciation	History of lactation	14676 (96.9)	0.75 (0.68~0.83)	12429 (96.7)	0.73 (0.66~0.81)	2530 (98.1)	0.82 (0.62~1.08)	260 (96.7)	0.66 (0.34~1.30)

eTable 7. Association between each reproductive factor and risk of incident stroke: multivariable Cox regression

		То	Total stroke		IS		ICH	SAH	
		N (%)	HR (95%CI)	N (%)	HR (95%CI)	N (%)	HR (95%CI)	N (%)	HR (95%CI)
	Lifetime lactation duration (years)	15139 (100)	1.07 (1.01~1.13)	12853 (100)	1.07 (1.00~1.14)*	2580 (100)	1.07 (0.92~1.23)	269 (100)	1.00 (0.99~1.00)
OCP	No OCP use History of OCP use	13983 (92.4) 1156 (7.6)	Reference 0.77 (0.73~0.82)	11842 (92.1) 1011 (7.9)	Reference 0.77 (0.72~0.82)	2441 (94.6) 139 (5.4)	Reference 0.73 (0.62~0.87)	240 (89.2) 29 (10.8)	Reference 1.12 (0.76~1.66)
	OCP use duration (years)	15139 (100)	0.94 (0.92~0.96)	12853 (100)	0.94 (0.92~0.96)	2580 (100)	0.88 (0.82~0.94)	269 (100)	1.01 (0.89~1.16)

Note: \*P < 0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; OCP, oral contraceptive pill. HR was adjusted for age at baseline, marital status, residential status, education level, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension.

### eTable 8. Sensitivity analysis

		Total stroke	IS	ICH	SAH
			HR	(95%CI)	
		Excluding participants	diagnosed stroke within the	e first 2 years of follow-up <sup>#</sup> (N	N=120,094)
	Q1 (<31.0 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.92~1.09)	1.00 (0.75~1.33)
RLS	Q2 (31.0-32.9 years)	0.96 (0.92~1.00)	0.96 (0.92~1.01)	0.94 (0.85~1.04)	1.01 (0.73~1.40)
KLS	Q3 (33.0-35.9 years)	0.92 (0.90~0.95)	0.92 (0.89~0.95)	0.95 (0.88~1.02)	1.08 (0.85~1.36)
	Q4 (≥36.0 years)	0.93 (0.90~0.96)	0.93 (0.90~0.97)	0.84 (0.77~0.92)	1.14 (0.90~1.46)
	Q1 (<23.5 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.75~1.33)
EEE	Q2 (23.5-27.2 years)	0.9 (0.87~0.94)	0.91 (0.88~0.95)	0.91 (0.84~0.99)	0.93 (0.70~1.23)
EEE	Q3 (27.3-30.6 years)	0.83 (0.80~0.86)	0.84 (0.81~0.88)	0.80 (0.73~0.88)	1.01 (0.78~1.32)
	Q4 (≥30.7 years)	0.83 (0.80~0.87)	0.84 (0.81~0.88)	0.71 (0.63~0.80)	1.21 (0.91~1.59)
	Q1 (<29.3 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.75~1.33)
TEE	Q2 (29.3-32.4 years)	0.91 (0.88~0.94)	0.91 (0.87~0.94)	0.92 (0.84~1.00)*	0.96 (0.73~1.26)
TEE	Q3 (32.5-35.2 years)	0.85 (0.82~0.88)	0.84 (0.81~0.87)	0.88 (0.80~0.96)	1.15 (0.89~1.49)
	Q4 (≥35.3 years)	0.84 (0.81~0.87)	0.84 (0.81~0.87)	0.80 (0.73~0.89)	1.15 (0.88~1.49)
				e of stroke during follow-up <sup>#</sup>	
	Q1 (<31.0 years)	1.00 (0.97~1.03)	1.00 (0.96~1.04)	1.00 (0.91~1.09)	1.00 (0.69~1.45)
RLS	Q2 (31.0-32.9 years)	0.96 (0.92~1.00)	0.97 (0.92~1.01)	0.94 (0.84~1.05)	1.05 (0.70~1.58)
<b>KLS</b>	Q3 (33.0-35.9 years)	0.94 (0.91~0.97)	0.93 (0.90~0.96)	0.97 (0.89~1.05)	1.25 (0.95~1.65)
	Q4 (≥36.0 years)	0.95 (0.92~0.98)	0.96 (0.93~0.99)	0.87 (0.79~0.95)	1.36 (1.02~1.82)
	Q1 (<23.5 years)	1.00 (0.97~1.03)	1.00 (0.96~1.04)	1.00 (0.92~1.08)	1.00 (0.69~1.45)
EEE	Q2 (23.5-27.2 years)	0.91 (0.88~0.94)	0.92 (0.89~0.95)	0.87 (0.80~0.95)	0.94 (0.66~1.33)
LEL	Q3 (27.3-30.6 years)	0.86 (0.83~0.89)	0.87 (0.84~0.90)	0.80 (0.72~0.88)	1.04 (0.75~1.44)
	Q4 (≥30.7 years)	0.86 (0.83~0.89)	0.87 (0.84~0.91)	0.74 (0.65~0.85)	1.46 (1.06~2.00)
	Q1 (<29.3 years)	1.00 (0.97~1.03)	1.00 (0.96~1.04)	1.00 (0.92~1.09)	1.00 (0.69~1.44)
TEE	Q2 (29.3-32.4 years)	0.92 (0.89~0.95)	0.92 (0.89~0.95)	0.92 (0.84~1.00)	0.93 (0.66~1.32)
IEE	Q3 (32.5-35.2 years)	0.86 (0.83~0.89)	0.86 (0.82~0.89)	0.88 (0.79~0.97)	1.13 (0.81~1.56)
	Q4 (≥35.3 years)	0.87 (0.84~0.90)	0.87 (0.84~0.90)	0.85 (0.76~0.95)	1.41 (1.05~1.89)
		Excluding participants	taking related drugs## (N=1	13,474)	
	Q1 (<31.0 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.92~1.08)	1.00 (0.76~1.32)
RLS	Q2 (31.0-32.9 years)	0.97 (0.93~1.01)	0.97 (0.93~1.02)	0.96 (0.87~1.06)	0.96 (0.69~1.33)
KL3	Q3 (33.0-35.9 years)	0.94 (0.91~0.97)	0.93 (0.90~0.97)	0.96 (0.89~1.04)	1.05 (0.83~1.33)
	Q4 (≥36.0 years)	0.96 (0.93~0.99)	0.96 (0.93~0.99)	0.92 (0.84~1.00)*	1.22 (0.96~1.55)
EEE	Q1 (<23.5 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.76~1.32)

		Total stroke	IS	ICH	SAH
			HR	(95%CI)	
	Q2 (23.5-27.2 years)	0.91 (0.88~0.95)	0.92 (0.89~0.96)	0.89 (0.82~0.96)	0.93 (0.71~1.22)
	Q3 (27.3-30.5 years)	0.86 (0.83~0.89)	0.87 (0.84~0.90)	0.83 (0.75~0.91)	0.96 (0.73~1.25)
	Q4 (≥30.6 years)	0.86 (0.83~0.90)	0.87 (0.84~0.91)	0.75 (0.67~0.85)	1.23 (0.94~1.62)
	Q1 (<29.3 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.76~1.32)
TEE	Q2 (29.3-32.2 years)	0.92 (0.88~0.95)	0.91 (0.87~0.94)	0.94 (0.86~1.02)	0.92 (0.70~1.22)
TEE	Q3 (32.3-35.2 years)	0.87 (0.84~0.91)	0.87 (0.83~0.90)	0.88 (0.81~0.97)	1.12 (0.88~1.44)
	Q4 (≥35.3 years)	0.87 (0.84~0.90)	0.86 (0.83~0.89)	0.87 (0.79~0.96)	1.20 (0.93~1.55)
		<b>Excluding participants</b>	with related diseases## (N=1	13,752)	
	Q1 (<31.0 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.92~1.08)	1.00 (0.76~1.31)
RLS	Q2 (31.0-32.9 years)	0.96 (0.92~1.00)*	0.95 (0.91~1.00)*	0.95 (0.87~1.05)	0.95 (0.69~1.32)
KLS	Q3 (33.0-35.9 years)	0.95 (0.92~0.98)	0.94 (0.91~0.97)	0.98 (0.91~1.06)	1.13 (0.91~1.41)
	Q4 (≥36.0 years)	0.97 (0.94~1.00)	0.97 (0.93~1.00)	0.90 (0.83~0.98)	1.25 (1.00~1.57)
	Q1 (<23.5 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.76~1.31)
PPP	Q2 (23.5-27.2 years)	0.91 (0.88~0.95)	0.92 (0.89~0.95)	0.91 (0.84~0.98)	0.84 (0.64~1.10)
EEE	Q3 (27.3-30.5 years)	0.86 (0.83~0.89)	0.87 (0.83~0.90)	0.84 (0.76~0.92)	1.02 (0.79~1.31)
	Q4 (≥30.6 years)	0.85 (0.82~0.89)	0.85 (0.82~0.89)	0.75 (0.66~0.84)	1.27 (0.98~1.65)
	Q1 (<29.3 years)	1.00 (0.97~1.04)	1.00 (0.96~1.04)	1.00 (0.93~1.08)	1.00 (0.76~1.31)
TEE	Q2 (29.3-32.3 years)	0.93 (0.89~0.96)	0.92 (0.88~0.95)	0.93 (0.86~1.01)	0.97 (0.74~1.26)
TEE	Q3 (32.4-35.2 years)	0.88 (0.85~0.91)	0.87 (0.83~0.90)	0.90 (0.82~0.99)	1.13 (0.88~1.46)
	Q4 (≥35.3 years)	0.88 (0.85~0.92)	0.87 (0.84~0.91)	0.85 (0.77~0.93)	1.36 (1.07~1.72)

Notes: \*P < 0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

<sup>#</sup>HR was adjusted for age at baseline, marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension. <sup>##</sup>HR was adjusted for age at baseline, marital status, residential status, education level, occupation, household income, body mass index, waist circumference, tobacco smoking, second hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day. Related drugs included angiotensin converting enzyme inhibitors (ACEI), aspirin, beta-blocker, calcium antagonist, diuretics, statins. Related diseases included cancer, chronic heart disease, psychic disorders, rheumatic heart disease, kidney disease.

eTable 9. Association between indicators of lifetime cumulative exposure due to reproductive factors and risk of incident stroke: age-stratified multivariable Cox

	•
regre	ession
10510	001011

		Total stroke	IS	ICH	SAH
		I Utal Sti UKC		(95%CI) <sup>#</sup>	0/11
	RLS			(10,001)	
	Q1 (<29.0 years)	1.00 (0.78~1.28)	1.00 (0.76~1.31)	1.00 (0.49~2.04)	1.00 (1.00~1.00)
40≤age<50	Q2 (29.0-30.9 years)	1.26 (1.04~1.51)	1.21 (0.99~1.48)	1.79 (1.12~2.87)	1.55 (0.32~7.41)
(n=7,216)	Q3 (31.0-32.9 years)	1.04 (0.86~1.26)	0.91 (0.73~1.12)	2.13 (1.39~3.26)	2.58 (0.72~9.23)
	Q4 (≥33.0 years)	1.03 (0.84~1.25)	0.96 (0.77~1.19)	1.27 (0.71~2.26)	2.03 (0.52~7.95)
	Q1 (<31.0 years)	1.00 (0.94~1.06)	1.00 (0.93~1.07)	1.00 (0.86~1.16)	1.00 (0.66~1.51)
50≤age<60	Q2 (31.0-33.9 years)	0.99 (0.94~1.04)	0.98 (0.92~1.03)	1.10 (0.97~1.24)	0.98 (0.69~1.38)
(n=63,673)	Q3 (34.0-35.9 years)	0.94 (0.89~0.99)	0.93 (0.87~0.99)	1.00 (0.87~1.16)	0.91 (0.62~1.35)
	Q4 (≥36.0 years)	0.96 (0.91~1.01)	0.95 (0.91~1.01)	0.93 (0.82~1.06)	1.03 (0.74~1.43)
	Q1 (<30.0 years)	1.00 (0.94~1.07)	1.00 (0.93~1.07)	1.00 (0.87~1.15)	1.00 (0.58~1.73)
60≤age<70	Q2 (30.0-32.9 years)	0.97 (0.92~1.02)	0.99 (0.94~1.04)	0.88 (0.78~0.99)	0.72 (0.44~1.18)
(n=39,007)	Q3 (33.0-35.9 years)	0.94 (0.90~0.98)	0.94 (0.89~0.99)	0.90 (0.81~1.01)	1.47 (1.06~2.03)
	Q4 (≥36.0 years)	0.95 (0.91~0.99)	0.96 (0.92~1.01)	0.84 (0.75~0.94)	1.60 (1.18~2.18)
	Q1 (<30.0 years)	1.00 (0.92~1.09)	1.00 (0.91~1.10)	1.00 (0.84~1.20)	1.00 (0.45~2.24)
age≥70	Q2 (30.0-32.9 years)	0.99 (0.92~1.06)	0.99 (0.92~1.07)	0.91 (0.77~1.06)	1.04 (0.56~1.94)
(n=13,043)	Q3 (33.0-35.9 years)	0.99 (0.92~1.05)	0.98 (0.91~1.06)	0.97 (0.84~1.14)	0.93 (0.48~1.79)
	Q4 (≥36.0 years)	1.00 (0.93~1.08)	1.02 (0.94~1.10)	0.87 (0.73~1.03)	0.95 (0.49~1.83)
	EEE				
	Q1 (<23.9 years)	1.00 (0.81~1.24)	1.00 (0.79~1.27)	1.00 (0.60~1.66)	1.00 (1.00~1.00)
40≤age<50	Q2 (23.9-26.7 years)	0.95 (0.78~1.15)	0.96 (0.78~1.19)	0.95 (0.57~1.57)	1.00 (1.00~1.00)
(n=7,216)	Q3 (26.8-29.2 years)	0.87 (0.72~1.05)	0.80 (0.65~0.98)	1.14 (0.71~1.84)	1.53 (0.42~5.62)
	Q4 (≥29.3 years)	0.67 (0.54~0.85)	0.62 (0.49~0.79)	0.69 (0.35~1.37)	2.04 (0.56~7.50)
	Q1 (<25.5 years)	1.00 (0.95~1.06)	1.00 (0.94~1.06)	1.00 (0.89~1.12)	1.00 (0.70~1.43)
50≤age<60	Q2 (25.5-28.7 years)	0.86 (0.81~0.91)	0.84 (0.79~0.89)	0.96 (0.85~1.09)	0.83 (0.58~1.19)
(n=63,673)	Q3 (28.8-31.5 years)	0.79 (0.75~0.83)	0.80 (0.76~0.85)	0.65 (0.56~0.77)	0.74 (0.51~1.09)
	Q4 (≥31.6 years)	0.79 (0.74~0.84)	0.80 (0.75~0.85)	0.74 (0.62~0.88)	0.79 (0.53~1.18)
	Q1 (<22.1 years)	1.00 (0.95~1.05)	1.00 (0.94~1.06)	1.00 (0.90~1.12)	1.00 (0.64~1.57)
60≤age<70	Q2 (22.1-25.9 years)	0.91 (0.86~0.95)	0.90 (0.85~0.95)	0.96 (0.86~1.08)	1.13 (0.75~1.71)
(n=39,007)	Q3 (26-29.4 years)	0.87 (0.83~0.92)	0.89 (0.84~0.94)	0.77 (0.67~0.89)	1.25 (0.84~1.85)
	Q4 (≥29.5 years)	0.89 (0.84~0.93)	0.88 (0.83~0.93)	0.87 (0.76~1.01)	1.97 (1.40~2.77)

		Total stroke	IS	ІСН	SAH
				(95%CI) <sup>#</sup>	
	Q1 (<19.4 years)	1.00 (0.93~1.08)	1.00 (0.92~1.09)	1.00 (0.86~1.16)	1.00 (0.51~1.94)
age≥70	Q2 (19.4-23.5 years)	0.90 (0.83~0.96)	0.94 (0.86~1.01)	0.79 (0.67~0.93)	0.47 (0.21~1.03)
(n=13,043)	Q3 (23.6-27.4 years)	0.88 (0.82~0.95)	0.93 (0.86~1.01)	0.73 (0.61~0.88)	0.53 (0.25~1.10)
	Q4 (≥27.5 years)	0.86 (0.80~0.93)	0.90 (0.83~0.97)	0.73 (0.60~0.90)	0.64 (0.32~1.29)
	TEE				
	Q1 (<28.0 years)	1.00 (0.81~1.24)	1.00 (0.79~1.26)	1.00 (0.58~1.71)	1.00 (1.00~1.00)
40≤age<50	Q2 (28.0-30.3 years)	0.98 (0.81~1.19)	0.94 (0.76~1.16)	1.30 (0.83~2.04)	0.38 (0.05~3.01)
(n=7,216)	Q3 (30.4-32.5 years)	0.88 (0.73~1.07)	0.82 (0.66~1.01)	1.27 (0.79~2.05)	1.94 (0.55~6.86)
	Q4 (≥32.6 years)	0.71 (0.57~0.89)	0.70 (0.55~0.88)	0.69 (0.35~1.39)	0.86 (0.18~4.12)
	Q1 (<30.2 years)	1.00 (0.95~1.06)	1.00 (0.94~1.06)	1.00 (0.89~1.13)	1.00 (0.69~1.44)
50≤age<60	Q2 (30.2-33.0 years)	0.88 (0.83~0.93)	0.86 (0.81~0.91)	0.96 (0.85~1.09)	0.85 (0.59~1.24)
(n=63,673)	Q3 (33.1-35.7 years)	0.84 (0.80~0.89)	0.84 (0.79~0.89)	0.77 (0.66~0.89)	0.90 (0.62~1.31)
	Q4 (≥35.8 years)	0.78 (0.74~0.83)	0.78 (0.73~0.83)	0.77 (0.65~0.91)	0.95 (0.65~1.38)
	Q1 (<28.8 years)	1.00 (0.95~1.05)	1.00 (0.94~1.06)	1.00 (0.89~1.12)	1.00 (0.63~1.58)
60≤age<70	Q2 (28.8-32.0 years)	0.93 (0.89~0.98)	0.94 (0.89~0.99)	0.91 (0.81~1.02)	0.87 (0.55~1.38)
(n=39,007)	Q3 (32.1-35.2 years)	0.89 (0.85~0.94)	0.89 (0.84~0.94)	0.88 (0.78~1.01)	1.85 (1.34~2.56)
	Q4 (≥35.3 years)	0.91 (0.86~0.95)	0.91 (0.86~0.95)	0.86 (0.75~0.98)	1.55 (1.09~2.21)
	Q1 (<27.8 years)	1.00 (0.93~1.08)	1.00 (0.92~1.09)	1.00 (0.86~1.16)	1.00 (0.49~2.06)
age≥70	Q2 (27.8-31.0 years)	0.93 (0.87~1.01)	0.93 (0.86~1.01)	0.88 (0.74~1.03)	1.16 (0.63~2.14)
(n=13,043)	Q3 (31.1-34.4 years)	0.97 (0.90~1.04)	0.99 (0.92~1.07)	0.79 (0.66~0.95)	0.91 (0.45~1.82)
,	Q4 (≥34.5 years)	0.91 (0.85~0.99)	0.91 (0.84~0.99)	0.88 (0.73~1.05)	0.83 (0.40~1.72)

Notes: \**P*<0.05; HR and 95% CI in blue indicate a significant protective effect, whereas HR and 95% CI in red indicate a significant hazard effect. HR, hazard ratio; CI, confidence internal; RLS, reproductive lifespan; EEE, endogenous estrogen exposure; TEE, total estrogen exposure; IS, ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage. <sup>#</sup>HR was adjusted for marital status, residential status, education, occupation, household income, body mass index, waist circumference, tobacco smoking, second-hand smoking, alcohol consumption, physical activity in metabolic equivalent-hours/day, anticoagulation therapy, hypolipidemic therapy, diabetes, hypertension.